GRAIL's Galleri Multi-Cancer Blood Test PMA Set For FDA Advisory Committee Review On Sept. 23
GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel
GRAIL's blood test that looks for early cancer signs is getting reviewed by FDA experts on September 23rd. This is an important checkpoint—it shows the test is being taken seriously, but we'll learn more about what experts think after the meeting.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.